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Glutamate-related genes have been associated with schizophrenia, but the results have been ambiguous
and difﬁcult to replicate. Homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA) and 3-methoxy-
4-hydroxyphenylglycol (MHPG) are the major degradation products of the monoamines dopamine,
serotonin and noradrenaline, respectively, and their concentrations in the cerebrospinal ﬂuid (CSF),
mainly HVA, have been associated with schizophrenia. In the present study, we hypothesized that CSF
HVA, 5-HIAA and MHPG concentrations represent intermediate phenotypes in the association between
glutamate-related genes and psychosis. To test this hypothesis, we searched for association between 238
single nucleotide polymorphisms (SNPs) in ten genes shown to be directly or indirectly implicated in
glutamate transmission and CSF HVA, 5-HIAA and MHPG concentrations in 74 patients with psychotic
disease. Thirty-eight nominally signiﬁcant associations were found. Further analyses in 111 healthy
controls showed that 87% of the nominal associations were restricted to the patients with psychosis.
Some of the psychosis-only-associated SNPs found in the D-amino acid oxidase activator (DAOA) and the
kynurenine 3-monooxygenase (KMO) genes have previously been reported to be associated with schi-
zophrenia. The present results suggest that CSF monoamine metabolite concentrations may represent
intermediate phenotypes in the association between glutamate-related genes and psychosis.
& 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Glutamate is the major excitatory neurotransmitter in the
central nervous system (CNS) and several lines of evidence suggest
association between the glutamatergic system and schizophrenia
(Cherlyn et al., 2010). Several glutamate-related genes have been
associated with schizophrenia, however the results have beenIreland Ltd. This is an open acces
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eou).difﬁcult to replicate in subsequent studies until recently, when a
genome wide association study of more than 100,000 individuals
found association between genes related to glutamatergic neuro-
transmission and the disorder (Schizophrenia Working Group of
the Psychiatric Genomics Consortium, 2014).
Homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA)
and 3-methoxy-4-hydroxyphenylglycol (MHPG) are the major
degradation products of the monoamines dopamine, serotonin
and noradrenaline, respectively, and their concentrations in the
cerebrospinal ﬂuid (CSF) are considered to reﬂect the turnover
rates of the monoamines in the CNS (Stanley et al., 1985; Wester
et al., 1990). Several lines of evidence suggest connections and
interactions in CNS between glutamate and the monoamine sys-
tems, mainly dopamine. Dopamine regulates the activity of glu-
tamatergic neurons in cortex, where as glutamatergic neurons
innervate dopamine cells in ventral tagmental area (Sesack et al.,
2003). Moreover, dopamine and glutamate modulate common
target neurons in various brain regions, including prefrontal cortex
and basal ganglia (Sesack et al., 2003). Glutamate is co-releaseds article under the CC BY-NC-ND license
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et al., 2014) and serotonin reuptake inhibitors modulate glutamate
synapses onto serotonergic neurons of the dorsal raphe nucleus
(Geddes et al., 2015). A synergistic regulation of glutamatergic
neurotransmission in cortex by the serotonin and norepinephrine
systems has also been reported (Yuen et al., 2014). Finally, the CSF
concentration of kynurenic acid, a glutamate receptor antagonist
(Schwarcz et al., 2012), has been reported to have positive inter-
correlations with both CSF HVA and 5-HIAA (Nilsson et al., 2007).
Investigating the association between gene variants and inter-
mediate phenotypes in psychotic individuals is a powerful ap-
proach that can result in more robust results as well as a deeper
understanding of the genotype-phenotype associations (Freimer
and Sabatti, 2003; Bilder et al., 2009). An intermediate phenotype
can be deﬁned as a mechanism-related manifestation of a complex
phenotype, in our case the psychotic disorder (Goldman and Ducci,
2007). An endophenotype should meet speciﬁc criteria, i.e. herit-
ability, disease association, state-independence and co-segrega-
tion within families (Gottesman and Gould, 2003). Moreover, for
complex diseases, such as schizophrenia, it has been proposed that
an endophenotype should be found at a higher rate in non-af-
fected family members relative to general population (Gottesman
and Gould, 2003).
The term intermediate phenotype is used by many authors for
traits that have not been formally shown to meet the criteria for
endophenotypes (Goldman and Ducci, 2007). In the present study,
we have used the term intermediate phenotypes to characterize
the monoamine metabolite concentrations relative to psychosis, as
they have been reported to be heritable and to some extend psy-
chosis-related, but do not formally fulﬁll all the endophenotype-
related criteria required.
Regarding heritability, a study in human twins has shown that
CSF MHPG is under major genetic inﬂuence, whereas CSF 5-HIAA
and HVA are under both genetic and environmental inﬂuence
(Oxenstierna et al., 1986). Studies in other primates also indicate
that monoamine metabolite CSF concentrations are partially under
genetic inﬂuence (Higley et al., 1993; Rogers et al., 2004). Re-
garding disease association, schizophrenia has been associated
with monoamine metabolite concentrations, mainly HVA. HVA
concentrations have been reported to be signiﬁcantly lower in
drug-free patients with schizophrenia compared to controls
(Bjerkenstedt et al., 1985; Lindström, 1985; Wieselgren and Lind-
strom, 1998). Increased CSF MHPG concentrations have also been
associated with psychosis (Hsiao et al., 1993).
N-methyl-D-aspartate receptors (NMDARs), one of the main
glutamate receptor classes, play a critical role in neurodevelop-
ment, learning and memory (Hirasawa et al., 2003; Riedel et al.,
2003). It has been proposed that a hypofunction of the NMDARs is
implicated in the pathophysiology of schizophrenia, generating
cognitive, negative and positive symptoms (Javitt and Zukin, 1991;
Krystal et al., 1994; Javitt, 2008; Labrie and Roder, 2010). In the
present study, we chose two genes encoding NMDAR subunits, i.e.
glutamate receptor, ionotropic, N-methyl-D-aspartate, subunit 1
(GRIN1) encoding the NR1 subunit and glutamate receptor, iono-
tropic, N-methyl-D-aspartate, subunit 2B (GRIN2B) encoding the
NR2B subunit, being the most studied NMDAR subunits-related
genes in schizophrenia. (www.szgene.org). GRIN1 and GRIN2B are
located on chromosomes 9q34.3 and 12p12, respectively.
The D-amino acid oxidase activator (DAOA) protein is located in
various regions of CNS, mainly amygdala and nucleus caudatus
(Chumakov et al., 2002). DAOA regulates the function of D-amino
acid oxidase (DAO), a ﬂavoprotein catalyzing the oxidative dea-
mination of D-amino acids, including D-DOPA and D-serine, a co-
agonist of the NMDARs (Wu et al., 2006; Kawazoe et al., 2007). The
DAO gene is located on chromosome 12q24, whereas the DAOA
gene is located on chromosome 13q34.Disrupted in schizophrenia 1 (DISC1) is a protein, involved in
neurodevelopment, plasticity and migration of neurons (Thomson
et al., 2013). It affects glutamate neurotransmission in several
ways, mainly by modulating serine racemase, an enzyme that
generates D-serine, altering the NMDAR neurotransmission (Sny-
der and Gao, 2013). The DISC1 gene is located on chromosome
1q42.1.
Brain-derived neurotrophic factor (BDNF) is the most expressed
neurotrophic factor in the brain and is considered to play an im-
portant role in the development, survival and regeneration of
neurons (Balaratnasingam and Janca, 2012; Nurjono et al., 2012).
BDNF is implicated in the glutamatergic as well as dopamine and
serotonergic neurotransmitter systems (Nurjono et al., 2012). The
BDNF gene is located on chromosome 11p13.
Dysbindin is a protein implicated in synaptic structure and
signaling, as well as in neurodevelopment (Benson et al., 2001;
Ghiani et al., 2010). It is involved in both dopamine and glutamate
neurotransmission in CNS (Talbot et al., 2004; Weickert et al.,
2004). Dysbindin is encoded by the dystrobrevin-binding protein 1
(DTNBP1) gene, located on chromosome 6p22.3.
Indoleamine 2,3-dioxygenase (IDO), tryptophan 2,3-dioxygen-
ase (TDO) and kynurenine 3-monooxygenase (KMO) are important
enzymes implicated in the kynurenine pathway of tryptophan
degradation (Schwarcz et al., 2012). Kynurenic acid and other
neuroactive metabolites of this pathway are implicated in gluta-
matergic, dopaminergic and noradrenergic neurotransmissions
(Myint and Kim, 2014). Dysregulation of the kynurenine pathway
has also been associated with mental disorders, mainly schizo-
phrenia (Schwarcz et al., 2012). IDO, TDO and KMO are encoded by
the IDO1, TDO2 and KMO genes, located on chromosomes 8p12-
p11, 4q31-q32 and 1q42-q44, respectively.
In the present study, we considered the major metabolites of
dopamine, serotonin, and noradrenaline as intermediate steps
between glutamate-related genes and psychosis. We hypothesized
that single nucleotide polymorphisms (SNPs) in these genes affect
the CSF concentrations of HVA, 5-HIAA, and MHPG in psychotic
patients.2. Methods
2.1. Subjects
Patients with psychosis, recruited among inpatients from four psychiatric
university clinics in Stockholm County between the years 1973 and 1987, were
asked to participate in pharmacological and/or biological research projects (Bjer-
kenstedt et al., 1977; Wode-Helgodt et al., 1977; Härnryd et al., 1984; Oxenstierna
et al., 1996). All participants were observed for at least 48 hours without any an-
tipsychotic medication and CSF samples were drawn by a lumbar puncture.
Seventy-four psychotic patients (45 men and 29 women) participated in the
present study. The mean age (standard deviation) at lumbar puncture was 30.4
(7.2) years, whereas the mean age of disease onset (standard deviation) was 27.6
(7.8) years. Thirty-ﬁve percent of the patients (N¼26) were treated with anti-
psychotic medication, whereas 49% (N¼36) were free from antipsychotics since
three weeks or more. Sixty-four patients were diagnosed with schizophrenia
spectrum disorder (schizophrenia n¼60 and schizoaffective disorder n¼4),
whereas ten patients were diagnosed with other psychosis (psychosis not other-
wise speciﬁed (NOS) n¼7, delusional disorder n¼1, bipolar disorder n¼1, alcohol
induced psychotic disorder n¼1).
Three to 34 years after the ﬁrst investigation, the psychotic patients were asked
to participate in genetic research studies and whole blood was drawn for geno-
typing. The participants were asked to undergo a structured interview (Spitzer
et al., 1988) and permit the researchers to retrieve their medical records. Available
records were scrutinized by researchers in order to obtain a life-time diagnosis
according to DSM-III-R and DSM-IV. In 2010, hospital discharge diagnoses were
obtained from the Swedish psychiatric inpatient register (SPIR), a register covering
all inpatient hospitalizations in Sweden since 1973. Psychiatric diagnoses were
recorded for each hospitalization according to the International Classiﬁcation of
Diseases, 8th, 9th or 10th revisions. Most patients had experienced several hospi-
talizations. However, each patient obtained one diagnosis, following a diagnostic
hierarchy (Ekholm et al., 2005; Vares et al., 2006). The ﬁnal diagnoses were based
Table 1
Minor allele frequencies (MAF), p-values for Hardy–Weinberg equilibrium tests
(HWE) and p-values (P) from nominal associations between single nucleotide
polymorphisms (SNPs) and cerebrospinal ﬂuid homovanillic acid (HVA) con-
centrations in psychotic patients. Corresponding association statistics among
healthy controls.
Patients with psychosis
(n¼74; 45 men, 29
women)
Healthy controls (n¼111;
63 men, 48 women)
HVA mean (S.D.) 178.6 (79.3) nmol/l 167.5 (68.4) nmol/l
Gene SNP MAF
(%)
HWE P MAF
(%)
HWE P
DISC1 rs12046794 11 0.590 0.001 9 0.173 0.435
DISC1 rs1934909 14 1.000 0.007 14 0.123 0.964
DISC1 rs10158776 2 1.000 0.013 1 1.000 0.970
IDO1 rs6991530 14 1.000 0.015 14 1.000 0.290
DAO rs17041020 7 1.000 0.021 5 1.000 0.040
DISC1 rs823162 7 0.042 0.022 5 1.000 0.402
DISC1 rs4325116 39 0.462 0.034 37 0.838 0.904
DISC1 rs4385690 18 1.000 0.038 24 0.203 0.717
DAOA rs1421292 43 0.344 0.040 42 0.561 0.006
DISC1 rs1322783 12 0.277 0.043 15 0.280 0.878
DAOA rs3916971 47 0.066 0.045 47 0.849 0.009
DISC1 rs16854967 14 0.609 0.049 14 0.468 0.925
DAO rs2070586 14 1.000 0.049 19 0.355 0.790
Table 2
Minor allele frequencies (MAF), p-values for Hardy–Weinberg equilibrium tests
(HWE) and p-values (P) from nominal associations between single nucleotide
polymorphisms (SNPs) and 5-hydroxyindoleacetic acid (5-HIAA) cerebrospinal
ﬂuid concentrations in psychotic patients. Corresponding association statistics
among healthy controls.
Patients with psychosis
(n¼74; 45 men, 29
women)
Healthy controls (n¼111;
63 men, 48 women)
5-HIAA mean (S.D.) 93.1 (34) nmol/l 90.8 (36.2) nmol/l
Gene SNP MAF
(%)
HWE P MAF
(%)
HWE P
DAOA rs3918342 47 0.647 0.002 46 0.703 0.072
DISC1 rs1934909 14 1.000 0.010 14 0.123 0.400
DAOA rs1421292 43 0.344 0.010 42 0.561 0.085
DISC1 rs1331056 45 0.154 0.012 40 0.844 0.131
DAOA rs3916971 47 0.066 0.018 47 0.849 0.093
GRIN1 rs28489906 47 0.100 0.025 48 1.000 0.500
KMO rs1932441 29 0.395 0.026 36 0.680 0.093
IDO1 rs6991530 14 1.000 0.028 14 1.000 0.194
DISC1 rs2806465 50 0.062 0.033 45 0.443 0.033
KMO rs12410855 36 0.079 0.034 36 0.681 0.946
DAOA rs778293 43 0.237 0.034 42 1.000 0.049
DISC1 rs12046794 11 0.590 0.035 8 0.484 0.365
DISC1 rs17820909 10 1.000 0.036 6 1.000 0.597
DTNBP1 rs12525702 9 0.438 0.040 8 0.115 0.250
DTNBP1 rs3829893 11 0.031 0.042 10 0.321 0.656
DISC1 rs9726024 34 0.606 0.048 34 0.403 0.158
D. Andreou et al. / Psychiatry Research 229 (2015) 497–504 499on the SPIR, as it was not possible to retrieve medical records from all patients and
some of the patients were not willing to participate in a diagnostic interview.
These 74 patients have been also included in a recent study, searching for as-
sociation between genes encoding enzymes implicated in monoamine metabolism
and CSF monoamine metabolite concentrations (Andreou et al., 2014).
For SNPs that were nominally associated with CSF HVA, 5-HIAA or MHPG
concentrations in psychotic patients, analyses in healthy subjects were performed,
in order to evaluate whether the effects of the associated SNPs were restricted to
the patients. Healthy unrelated Caucasians (n¼111; 63 men and 48 women) were
included in the study for that purpose. CSF samples were drawn by lumbar
puncture between 1973 and 1987. Eight to 20 years after this ﬁrst investigation, the
healthy controls were interviewed to re-assess the absence of psychiatric morbidity
(Jönsson et al., 2004) and whole blood was drawn for genotyping.
Some or all of the 111 controls have previously participated in studies searching
for association between gene variants and CSF monoamine metabolite concentra-
tions in healthy individuals only (Jönsson et al., 1996, 1997, 1998, 2000; Damberg
et al., 2004; Jönsson et al., 2004, 2008; Andreou et al., 2010; Annerbrink et al., 2010;
Andreou et al., 2011, 2012). Recently, the 111 controls were included in a study
searching for association between genes implicated in monoamine metabolism and
CSF monoamine metabolite concentrations in psychotic patients and healthy in-
dividuals (Andreou et al., 2014).
The study was conducted in accordance with the Declaration of Helsinki and
approved by the Ethics Committee of the Karolinska University Hospital. Written
informed consent was obtained from all participants.
2.2. CSF monoamine metabolite concentrations
12.5 ml CSF was drawn by lumbar puncture from all subjects between 8 and
9 a.m. after at least 8 h of bed-rest and absence of food intake or smoking. All
participants were in a sitting or recumbent position during the procedure. 5-HIAA,
HVA, and MHPG CSF concentrations were measured by mass fragmentography
with deuterium-labeled internal standards (Swahn et al., 1976).
2.3. DNA analysis
Genomic DNA was extracted from whole blood (Geijer et al., 1994). Totally, 238
SNPs were genotyped from 10 genes, i.e. GRIN1 (n¼10), GRIN2B (n¼5), DAOA
(n¼19), DAO (n¼11), DISC1 (n¼122), BDNF (n¼10), DTNBP1 (n¼26), KMO (n¼25),
IDO1 (n¼3) and TDO2 (n¼7). These SNPs were either candidate SNPs (n¼42)
previously associated with schizophrenia, other mental disorders, monoamine
metabolite concentrations or having other known functionality, or tag-SNPs
(n¼196), selected using HapMap to cover the ten genes with an r2 threshold of 0.8.
The genotyping was performed using the Illumina BeadStation 500GX and the 768-
plex Illumina Golden Gate assay (Illumina Inc., San Diego, CA, USA) (Fan et al.,
2003).
2.4. Statistical analysis
Hardy–Weinberg equilibrium (HWE) was tested using exact signiﬁcance as
implemented in STATA 12.1. Minor allele frequencies were measured and normality
of residuals was checked graphically with STATA 12.1. The associations between
SNPs and HVA, 5-HIAA and MHPG CSF concentrations were tested by multiple
linear regression (STATA 12.1), where concentration was modeled as a linear
function of the allele count (of each SNP separately) and three to ﬁve covariates.
In the analyses of psychotic patients, gender, age at lumbar puncture, back-
length, diagnosis (i.e. schizophrenia spectrum psychosis or other psychosis) and
antipsychotic treatment were included as covariates. Antipsychotic treatment was
regarded as present if patients had taken antipsychotic medication during a three-
week period prior to the lumbar puncture. In the case of healthy controls, back-
length, gender and age at lumbar puncture were used as covariates.
In patients with psychosis, we conducted 714 tests, as we have tested 238 SNPs
separately for each of the three monoamine metabolites. Adjustments for multiple
testing were performed using a Bonferroni correction taking into account the
number of tests conducted (α¼7105).3. Results
SNPs (n¼238) in ten genes were genotyped in psychotic pa-
tients. The minor allele frequencies for the selected markers ran-
ged from 0% to 50%. The mean (standard deviation) concentrations
of the three monoamine metabolites were: HVA 178.6
(79.3) nmol/L; 5-HIAA 93.1 (34) nmol/L; MHPG 43.3 (9.3) nmol/L.
Thirteen, 16 and nine of the genotyped SNPs (Tables 1–3) were
nominally associated with CSF HVA, 5-HIAA and MHPGconcentrations, respectively. The residuals of the nominal asso-
ciations were approximately normally distributed. Two of the as-
sociated SNPs, i.e. DISC1 rs823162 and DTNBP1 rs3829893, showed
departure from Hardy–Weinberg equilibrium (p-valueo0.05)
(Tables 1 and 2). Taking into account the total number of tests
conducted, we applied a Bonferroni correction
(α¼0.05/714¼7105) and none of the nominal associations
remained signiﬁcant.
In order to evaluate how the Swedish in-patient resister-based
diagnoses, which were used as our ﬁnal diagnoses in the present
study, conformed to other diagnostic tools, separate analyses were
performed. Data from medical records were retrieved for 52 of the
Table 3
Minor allele frequencies (MAF), p-values for Hardy–Weinberg equilibrium tests
(HWE) and p-values (P) from nominal associations between single nucleotide
polymorphisms (SNPs) and 3-methoxy-4-hydroxyphenylglycol (MHPG) cere-
brospinal ﬂuid concentrations in psychotic patients. Corresponding association
statistics among healthy controls.
Patients with psychosis
(n¼74; 45 men, 29
women)
Healthy controls (n¼111;
63 men, 48 women)
MHPG mean (S.D.) 43.3 (9.3) nmol/l 41.7 (8.1) nmol/l
Gene SNP MAF
(%)
HWE P MAF
(%)
HWE P
KMO rs2275163 39 0.808 0.003 35 0.290 0.965
KMO rs4660103 33 1.000 0.003 29 0.242 0.558
KMO rs6677357 28 1.000 0.005 26 0.622 0.877
DISC1 rs1934909 14 1.000 0.015 14 0.123 0.574
KMO rs12138459 27 0.769 0.024 28 0.485 0.938
DISC1 rs2812385 42 0.474 0.026 28 1.000 0.775
DAOA rs1570709 22 0.165 0.026 22 0.096 0.447
IDO1 rs7010461 35 0.619 0.028 29 0.167 0.952
KMO rs2050516 47 0.647 0.044 40 0.691 0.714
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these individuals. Forty-four patients participated in a diagnostic
interview (Spitzer et al., 1988) and 91% of these patients displayed
a psychotic disorder according to the SCID-I algorithm. These re-
sults are in accordance with previous studies reporting that SPIR-
derived diagnoses of schizophrenia spectrum psychosis have a
high validity, as 85–94% of the patients received these diagnoses
when diagnostic evaluations were made using information from
medical records and a structured clinical interview (Vares et al.,
2006).
The mean CSF MHPG concentration was signiﬁcantly lower in
patients who were prescribed antipsychotics relative to anti-
psychotic-free patients, whereas mean CSF HVA and 5-HIAA con-
centrations were not found to be associated with antipsychotic
treatment. As we have included the use of antipsychotics as a
covariate in our analyses and moreover, our independent vari-
ables, i.e. the SNPs, are not expected to be associated with the
presence or absence of antipsychotic treatment, we consider that
the use of antipsychotics should not confound our analyses, even
in the case of MHPG.
The nominal associations (n¼38) between SNPs and mono-
amine metabolite concentrations in psychotic patients were tested
separately in 111 healthy unrelated individuals in order to ﬁnd out
whether these nominal associations were restricted to psychotic
patients or were also present in controls. The mean (standard
deviation) concentrations of the three monoamine metabolites
were: HVA 167.5 (68.4) nmol/L; 5-HIAA 90.8 (36.2) nmol/L; MHPG
41.7 (8.1) nmol/L. The minor allele frequency for the selected
markers ranged from 1% to 48% (Tables 1–3). No SNPs showed
deviation from the Hardy–Weinberg principles (Tables 1–3). The
residuals were approximately normally distributed. Three and two
nominal associations were found between SNPs and HVA and
5-HIAA, respectively in controls, whereas the majority of the
nominal associations (n¼33) were restricted to patients with
psychosis.
Additional analysis was conducted, investigating whether the
nominally signiﬁcant associations found in psychotic patients
were preserved in the drug-free psychotic patients. We found that
46% of the associations remained nominally signiﬁcant. More
speciﬁcally, 8/12, 6/16 and 3/9 of the nominal associations be-
tween SNPs and HVA, 5-HIAA and MHPG, respectively, were
preserved.4. Discussion
4.1. General considerations
To our knowledge, no other studies have searched for associa-
tions between gene variants and CSF monoamine metabolite
concentrations in patients with psychosis, with one exception. We
reported nominal associations between genes encoding enzymes
implicated in the monoamine metabolism and CSF monoamine
metabolite concentrations in psychosis (Andreou et al., 2014). Al-
most all the nominal associations were absent in healthy controls.
One of the investigated genes was the MAOB gene, located on
chromosome Xp11.23 and encoding the enzyme monoamine oxi-
dase B. Monoamine oxidases play an important role in the de-
gradation of biogenic amines, including dopamine, noradrenaline
and serotonin (Shih et al., 1999). The intronic MAOB SNP
rs5905512, applying a less conservative correction for multiple
testing,was found to be signiﬁcantly associated with MHPG con-
centrations in psychotic men only, suggesting that a previously
reported association between this intronic SNP and schizophrenia
in men only (Carrera et al., 2009), may be mediated by nora-
drenergic mechanisms. The participants in the present study and
in the study investigating the above named genes were the same,
i.e. 74 patients with psychosis and 111 healthy individuals.
One main reason why the term intermediate phenotype has
been used throughout the present article instead for the term
endophenotype is the fact that the CSF monoamine metabolite
concentrations in patients with schizophrenia have been found to
be affected by a variety of factors, including the clinical state of the
disorder, the patients’ characteristics and the medication with
antipsychotics and thus cannot be considered as state in-
dependent. Global Assessment Scale scores, reﬂecting the clinical
state of the disorder, were negatively correlated with CSF HVA
concentrations in drug-free patients with schizophrenia (Houston
et al., 1986). CSF 5-HIAA concentrations have been associated with
negative and disorganization dimensions (Anand et al., 2002),
deﬁcit characteristics (Csernansky et al., 1990), hallucinations
(Gattaz et al., 1982) and delusions (Lindström, 1985). CSF HVA
concentrations have been associated with the psychosis dimension
in ﬁrst episode drug naive patients with schizophrenia (Anand
et al., 2002) as well as the patients’ social interest (Lindström,
1985). Regarding antipsychotics, quetiapine and olanzapine ad-
ministration have been found to be associated with a signiﬁcant
increase in CSF HVA (Scheepers et al., 2001; Nikisch et al., 2010).
Moreover, the correlation between HVA and 5-HIAA, found to be
almost linear in healthy individuals, was substantially lower in
untreated psychotic patients relative to controls and was nor-
malized after treatment with antipsychotics (Hsiao et al., 1993).
The majority of the nominally signiﬁcant associations found in
psychotic patients were absent in healthy controls. When we re-
stricted the analysis to the smaller group of patients not taking
antipsychotics approximately half of the nominal associations
were preserved. The decrease of nominal associations from 37 to
17 is likely a result of a decrease in power due to the decrease in
the number of individuals included in the analysis.
4.2. GRIN1, GRIN2B, DAOA and DAO
GRIN1 has been associated with schizophrenia in four out of 15
studies conducted (www.szgene.org), as well as with bipolar dis-
order (Mundo et al., 2003). In the present study, one intronic
GRIN1 SNP, i.e. rs28489906, was associated with 5-HIAA con-
centrations in psychotic patients and to our knowledge, this SNP
has not been ascribed any functionality or association with mental
disorders.
GRIN2B has been associated with schizophrenia in 5/13 studies
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(Martucci et al., 2006), autistic spectrum disorder (Yoo et al., 2012)
and attention deﬁcit hyperactivity disorder (Dorval et al., 2007).
The product of the GRIN2B gene, i.e. the NR2A subunit has been
reported to have reduced expression in the prefrontal cortex in
patients with major depression compared to controls (Feyissa
et al., 2009). No GRIN2B SNPs were associated with monoamine
metabolite concentrations in the present study.
DAOA has been associated with schizophrenia in 27/41 studies
with two positive meta-analyses (www.szgene.org), as well as
with major depression (Rietschel et al., 2008) and bipolar disorder
(Prata et al., 2008). DAOA has also been associated with response
to antipsychotic treatment (Pae et al., 2010) and progression of
prodromal syndromes to ﬁrst episode psychosis (Mossner et al.,
2010). Moreover, DAOA transgenic mice showed psychosis-asso-
ciated behavioral phenotypes that could be reversed by haloper-
idol (Otte et al., 2009). In the present study two, four and one
DAOA SNPs were nominally associated with CSF concentrations of
HVA, 5-HIAA and MHPG, respectively Tables 1–3).
DAOA rs3918342 has been associated with schizophrenia and
bipolar disorder (Korostishevsky et al., 2004; Schumacher et al.,
2004; Bass et al., 2009; Ma et al., 2009). This SNP has been re-
ported to modulate hippocampal and prefrontal cortex function in
subjects at high risk of schizophrenia (Hall et al., 2008). DAOA
rs778293 has also been associated with schizophrenia in in-
dependent studies (Korostishevsky et al., 2004; Ma et al., 2006,
2009) and a meta-analysis (Shi et al., 2008) as well as with me-
thamphetamine psychosis (Kotaka et al., 2009) and bipolar dis-
order (Zhang et al., 2009). In the present study, rs3918342 and
rs778293 were nominally associated with 5-HIAA concentrations
in psychotic patients. Rs778293 was also associated with 5-HIAA
in controls, whereas the association between rs3918342 and
5-HIAA was restricted to psychosis. We can therefore hypothesize
that an altered serotonin turnover rate in CNS, as reﬂected by the
CSF 5-HIAA concentration, may be an intermediate phenotype in
the previously reported association between rs3918342 and schi-
zophrenia. Rs3918342 showed the lowest p-value (0.002) in as-
sociation with 5-HIAA concentrations in psychotic patients in the
present study and is located 28 Kb downstream of the DAOA gene.
DAOA rs1421292 has been associated with schizophrenia
(Schumacher et al., 2004) and has been reported to modulate brain
activation in a verbal ﬂuency task in healthy subjects (Krug et al.,
2011). DAOA rs3916971 has also been associated with schizo-
phrenia (Korostishevsky et al., 2004) with a positive meta-analysis
(www.szgene.org). In the present study, rs1421292 and rs3916971
were associated with both CSF HVA and 5-HIAA in patients with
psychosis. Both SNPs were also associated with HVA in healthy
individuals, where as their associations with 5-HIAA were re-
stricted to psychotic patients, proposing that mainly serotonin
turnover in CNS may play a role in the previously reported asso-
ciations between these SNPs and schizophrenia. Rs1421292 and
rs3916971 are located 40 kbp and four kbp downstream of the
DAOA gene, respectively.
DAOA rs1570709 has been reported to be signiﬁcantly asso-
ciated with schizophrenia (Opgen-Rhein et al., 2008). In the pre-
sent study, rs1570709 was found to be associated with MHPG
concentrations in psychotic patients, suggesting that noradrenalin
turnover rates in CNS may play a role in the association between
the SNP and the disorder.
DAO has been associated with schizophrenia in 6/19 studies
(www.szgene.org), as well as with autism spectrum disorders in
an independent study (Chung et al., 2007). We found two intronic
DAO SNPs, i.e. rs2070586 and rs17041020, to be nominally asso-
ciated with HVA concentrations in psychotic patients. Rs2070586
has previously been reported to be signiﬁcantly associated with
schizophrenia in both men and women (Kim et al., 2010) and ourresult supports the notion that this association may be mediated
by dopaminergic mechanisms.
4.3. DISC1, BDNF and DTNBP1
DISC1 has been associated with schizophrenia in 31/45 studies
conducted, as well as with bipolar disorder (Hennah et al., 2009;
Schosser et al., 2010) and autism (Zheng et al., 2011). In the present
study, eight, six and two SNPs were nominally associated with CSF
HVA, 5-HIAA and MHPG concentrations, respectively. To our
knowledge, none of these SNPs have been associated with schi-
zophrenia or other mental disorders. All but one of the associated
SNPs are related to non coding RNA regions (www.gwascentral.
org).
Several lines of evidence have associated BDNF with schizo-
phrenia (Nurjono et al., 2012) and the BDNF gene has been asso-
ciated with the disorder in 11/53 studies conducted (www.szgene.
org). BDNF SNPs have also been associated with CSF MHPG con-
centrations in healthy Caucasians (Jönsson et al., 2008). In the
present study, no BDNF SNPs were associated with HVA, 5-HIAA or
MHPG concentrations in patients with psychosis.
DTNBP1 has been associated with schizophrenia in 23/62 stu-
dies conducted (www.szgene.org) as well as with bipolar disorder
(Gaysina et al., 2009) and major depression (Kim et al., 2008).
DTNBP1 SNPs have also been associated with CSF HVA and 5-HIAA
concentrations in healthy humans (Andreou et al., 2011). To our
knowledge, no studies have searched for association between
DTNBP1 gene variants and monoamine metabolite concentrations
in schizophrenia. In the present study, two SNPs, i.e. rs12525702
and rs3829893 were associated with CSF 5-HIAA concentrations.
These SNPs are related to non coding RNA regions (www.gwas
central.org) and have not been associated with mental disorders.
4.4. KMO, IDO1 and TDO2
KMO has been associated with schizophrenia in the ﬁrst of two
independent samples tested in an association study (Aoyama et al.,
2006) as well as with psychotic features in bipolar disorder (La-
vebratt et al., 2014). In the present study, two KMO SNPs, i.e. the
intronic rs1932441, and the exonic rs12410855 were associated
with CSF 5-HIAA concentrations and ﬁve intronic KMO SNPs, i.e.
rs2275163, rs4660103, rs6677357, rs12138459, rs2050516 were
associated with CSF MHPG concentrations in patients with psy-
chosis. One of the SNPs associated with MHPG concentrations, i.e.
rs2275163, has been previously associated with schizophrenia in
the ﬁrst of two independent set of samples analyzed (Aoyama
et al., 2006) and we could therefore hypothesize that the reported
association may be mediated by noradrenergic mechanisms. In-
terestingly, rs2275163 has been also reported to be associated with
visuospatial working memory and predictive pursuit in a com-
bined sample of psychotic patients and controls (Wonodi et al.,
2011).
To our knowledge, no candidate gene studies have searched for
association between IDO1 and schizophrenia and no genome wide
association studies have shown evidence of association either. In
the present study, rs6991530 was nominally associated with HVA
and 5-HIAA, whereas rs7010461 was nominally associated MHPG.
To our knowledge, these SNPS have not been associated with
mental disorders or ascribed any functionality.
A complex genotype including a TDO2 SNP, i.e. rs2271537 and
SNPs from two other kynurenine pathway-related genes has been
signiﬁcantly associated with schizophrenia (Miller et al., 2009).
However, rs2271537 alone was not associated with the disorder
(Miller et al., 2009). Rs2271537 was included as a candidate SNP in
the present study and was not associated with CSF HVA, 5-HIAA or
MHPG concentrations in psychotic patients.
D. Andreou et al. / Psychiatry Research 229 (2015) 497–5045024.5. Limitations
The major limitation of the present study is the relatively small
number of patients and controls relative to the large number of
conducted tests. This issue results in a limited power to detect
possible associations after correction for multiple testing. More-
over, the associations found need replications in independent
studies. Although none of the participating patients took anti-
psychotics during the last 48 hours prior to lumbar puncture, 35%
of the patients were not without antipsychotics during the last
three-week period. This is also a limitation of the present study,
especially in the associations concerning MHPG, as we have found
that the mean CSF MHPG concentration was signiﬁcantly lower in
patients on antipsychotics compared to antipsychotic-free
patients.
4.6. Conclusions
In patients with psychosis, we have found nominally signiﬁcant
associations between SNPs in glutamate-related genes and dopa-
mine, serotonin and noradrenaline turnover rates, as reﬂected by
the CSF concentrations of HVA, 5-HIAA and MHPG, respectively.
The majority of the nominal associations (87%) were restricted to
patients with psychosis and were absent in healthy controls.
Moreover, some of the associated SNPs in DAOA and KMO have
been reported to be associated with schizophrenia, proposing that
the previously reported associations may be modulated by ser-
otonergic and noradrenergic mechanisms. Taken together, the
present results suggest that CSF monoamine metabolite con-
centrations may represent intermediate phenotypes in the asso-
ciation between glutamate-related genes and psychosis.Competing interests
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